Masayuki Shirasawa, Tatsuya Yoshida, Kouya Shiraishi, Naoko Goto, Shigehiro Yagishita, Tatsuya Imabayashi, Yuji Matsumoto, Ken Masuda, Yuki Shinno, Yusuke Okuma, Yasushi Goto, Hidehito Horinouchi, Masaya Yotsukura, Yukihiro Yoshida, Kazuo Nakagawa, Katsuhiko Naoki, Takaaki Tsuchida, Ryuji Hamamoto, Noboru Yamamoto, Noriko Motoi, Takashi Kohno, Shun-Ichi Watanabe, Yuichiro Ohe
BACKGROUND: Delta-like ligand 3 (DLL3) is a therapeutic target in small-cell lung cancer (SCLC). However, how DLL3 expression status affects the tumor microenvironment (TME) and clinical outcomes in SCLC remains unclear. METHODS: This retrospective study included patients with postoperative limited-stage (LS)-SCLC and extensive-stage (ES)-SCLC treated with platinum and etoposide (PE) plus anti-programmed cell death ligand 1 (PD-L1) antibody. We investigated the relationship of DLL3 expression with TME, mutation status, tumor neoantigens, and immunochemotherapy...
September 20, 2023: British Journal of Cancer